India Large Volume Parenteral Market Size, Share & Trends Analysis Report By Application (Therapeutic Injections, Fluid Balance Injections, Nutritious Injections), By Volume, By End Use, And Segment Forecasts, 2021 - 2028

Report Overview

The India large volume parenteral market size was valued at USD 83.4 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.0% from 2021 to 2028. An increase in local manufacturing of Large Volume Parenteral (LVP) is contributing to the growth of the market in India. The presence of a large number of malnourished children, high natality, increasing rate of premature births, growing prevalence of cancer, and rising adoption of LVP formulations in various healthcare and home care settings for chronically ill geriatric patients are factors expected to drive the market. Diseases such as Crohn’s, esophageal cancer, ulcerative colitis, gastric cancer, head and neck cancer, and laryngeal cancer can affect the oral intake of food in patients. Their growing prevalence is, in turn, expected to drive the demand for the parenteral mode of drug administration, aiding the growth of the market for large volume parenteral.

Key benefits offered by parenteral formulations including lower postoperative inflammatory response, lower infection rates, improved postsurgical immune competence, adequate nutrient supply, and shorter hospital stays are positively impacting market growth.LVPs provide a faster method for drug administration for patients during surgery or while recovering in the hospital. Growing physician preference for single-dose administration of vaccines and drugs to treat chronic diseases is further driving the demand for LVPs. The market is expanding due to an increase in the number of surgeries performed and the growing number of patients with chronic and lifestyle diseases that require hospitalization.

The ongoing COVID-19 pandemic has positively impacted market growth owing to increasing adoption of LVPs for various applications and increasing physician’s preference towards single-dose drug administration for improving drug absorption, and faster and safer patient recovery. In addition, the rising prevalence of chronic diseases and malnutrition, along with rapid growth in the geriatric population is driving the adoption of LVPs. In addition, the increasing number of surgical procedures, ongoing COVID-19 pandemic, and presence of critically ill patients with a hampered physiological functioning of the enteral route are additional factors surging the adoption of parenteral nutrition as an alternate route of administration.

Severe malnutrition in pregnant women is associated with factors such as intrauterine growth restriction, preterm delivery, congenital malformations, low birth weight, and perinatal mortality. Parenteral nutrition is advisable for pregnant women whose nutritional requirements are not being fulfilled by enteral intake. Moreover, the adoption of LVPs as part of total parenteral nutrition is increasing for pregnant women, to help maintain or restore optimal nutritional status for the mother as well as fetus, when caloric intake by oral or enteral routes is not sufficient. In addition, it provides necessary nutritional requirements for fulfilling metabolic and anabolic needs without increasing the overall risk of complications.

The Indian government has undertaken many steps to reduce overall medical costs and healthcare expenditure. The rapid introduction of generic drugs in the market for large-volume parenteral has remained a major focus and is expected to benefit Indian pharmaceutical companies. The companies are adopting new business models and introducing innovative ideas to meet consumer expectations. Indian pharma companies may continue to grow organically and inorganically through acquisitions and partnerships, which in turn, drives the market. For instance, in November 2020, Grifols and B Braun formed an alliance to enhance therapy safety and pharmacy production output. Grifols’ Kiro and B Braun’s Safe Infusion Systems will be combined to provide solutions for safe automated drug mixtures and delivery systems.

Application Insights

In 2020, the nutritious injections segment dominated the market for large volume parenteral and held the largest revenue share of 47.1%. Its growth is attributed to the increase in demand for these formulations to fulfill adequate nutrition requirements and improve drug absorption for faster and effective results. Different combinations of nutrients are available at different concentrations for different requirements. Parenteral nutrition is selected when a patient experiences short bowel syndrome, extensive Crohn’s disease, high-output gastrointestinal fistula, intractable vomiting, radiation enteritis, and mucositis after chemotherapy. Nutritious injections also reduce risks associated with the treatment of chronic diseases and ensure smoother therapy.

The therapeutic injections application segment is anticipated to register the fastest growth rate during the forecast period owing to the increasing prevalence of life-threatening diseases and growing demand for safer, faster, and effective methods of drug administration in patients undergoing surgical procedures. Ongoing COVID-19 pandemic and the surging demand for these formulations owing to the rising patient population suffering from low immunity levels and prone to the incidence of neurological diseases, cardiac problems, cancers, and spinal injuries, to meet adequate nutritional requirements when enteral nutrition mode is insufficient, not possible, or contraindicated, has positively impacted the company sales and overall market growth.

End-use Insights

The hospitals and other healthcare facilities segment dominated the market for large volume parenteral and accounted for the largest revenue share of 97.7% in 2020. The segment is anticipated to register the fastest growth during the forecast period. The growth can be attributed to the increase in demand for these formulations among patients during surgery or while recovering in the hospital, as well as growing physician preferences for single-dose administration. In India, the prevalence of malnutrition has increased over the past few years. According to the 2018 State of Food Security and Nutrition in the World report, 195.9 million people are undernourished in India. The Total Parenteral Nutrition (TPN) is an essential preparation for malnutrition, used in hospitalized patients where enteral feeding is not feasible or for critical care patients with compromised gastrointestinal tract function.

The homecare facilities segment is expected to register significant growth during the forecast period owing to the growing geriatric population and increasing consumer interests in the adoption of at-home care. According to an article published by Economic Times in April 2019, the share of the older population-those aged 60 years or above-in India is projected to increase to around 20% in 2050. This has resulted in an increased number of home care services that can manage dose administration in the geriatric population. Moreover, benefits offered by formulations such as high bioavailability and delivery of safer and faster drug absorption, are likely to boost segment growth.

Volume Insights

By volume, the 500 ml segment dominated the India large volume parenteral market and accounted for the largest revenue share of 34.2% in 2020. Growing awareness among healthcare professionals about hospital-associated malnutrition, rising number of surgeries, increasing preference for single-dose administration of vaccines and drugs, growing need for a faster route of drug administration to avoid complications, and an increase in local manufacturing are factors expected to drive the demand for LVP, which, in turn, can boost this segment. Moreover, rising demand for LVP formulations among critically ill patients, an increasing number of ICU admissions, and growing prevalence of various chronic disorders such as cancer and diabetes, are additional factors expected to propel market growth.

On the other hand, the 100 ml injectable segment is anticipated to register the fastest growth rate during the forecast period. The increasing prevalence of chronic diseases and growing demand for LVP formulations for fulfilling adequate nutrition requirements, correcting electrolyte and fluid balance disturbances, and as a vehicle for administration of other drugs are key factors expected to drive this segment. For instance, patients weighing more than 50 kg and with no additional risk factors for hepatotoxicity, paracetamol infusion in 100 mL quantity is suggested for treating fever or pain, especially in post-surgery, when other means of administering medicine are not feasible or when the IV method is clinically suggested to urgently treat hyperthermia or pain. This, in turn, is anticipated to positively impact the growth of the segment.

Key Companies & Market Share Insights

Increasing investments in R&D, collaborations with other industry players, geographic expansions, and product differentiation are among the key strategies adopted by these companies for gaining a competitive edge in the market for large volume parenteral. For instance, in July 2017, Baxter acquired 100.0% of Claris Injectables, a division of Claris Lifesciences. This added to Baxter’s production capabilities for generic injectables and intravenous solutions, along with bags, vials, and ampoules. Some of the prominent players in the India large volume parenteral (LVP) market include:

• B. Braun Melsungen AG

• Fresenius Kabi AG

• Baxter

• Otsuka Pharmaceuticals

• Sichuan Kelun

• Albert David Ltd.

• BML Parenteral Drugs

India Large Volume Parenteral Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the India large volume parenteral market report on the basis of application, volume, and end use:

• Application Outlook (Revenue, USD Million, 2014 - 2028)

  • Therapeutic Injections

  • Fluid Balance Injections

  • Nutritious Injections

• Volume Outlook (Revenue, USD Million, 2014 - 2028)

  • 100 ml

  • 250 ml

  • 500 ml

  • 1,000 ml

  • 2,000 ml

• End-use Outlook (Revenue, USD Million, 2014 - 2028)

  • Hospitals and Other Healthcare Facilities

  • Home Care